Dynamic Markets Need Dynamic Pricing: Roche Explores Differential Pricing Strategies In Emerging Markets

Roche experiments with a variety of tactics, including second brands, patient assistant programs, supporting private insurance and other ways to drive volume in highly fragmented markets.

Roche has talked for a long time about pursuing innovation rather than branded generics in emerging markets. But investors and other stakeholders have openly wondered how Roche could do that and still make its drugs affordable to the majority of patients in countries like China, India and other emerging markets.

During its Feb. 1 and Feb. 3 quarterly earnings call from London and New York, respectively, Roche for the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.